ATE301131T1 - Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung - Google Patents

Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung

Info

Publication number
ATE301131T1
ATE301131T1 AT99972640T AT99972640T ATE301131T1 AT E301131 T1 ATE301131 T1 AT E301131T1 AT 99972640 T AT99972640 T AT 99972640T AT 99972640 T AT99972640 T AT 99972640T AT E301131 T1 ATE301131 T1 AT E301131T1
Authority
AT
Austria
Prior art keywords
retro
inverted
inverted peptides
drug
targeted against
Prior art date
Application number
AT99972640T
Other languages
English (en)
Inventor
Daniel Joseph O'mahony
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Application granted granted Critical
Publication of ATE301131T1 publication Critical patent/ATE301131T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99972640T 1998-11-19 1999-11-19 Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung ATE301131T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10903898P 1998-11-19 1998-11-19
PCT/IE1999/000117 WO2000031123A2 (en) 1998-11-19 1999-11-19 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof

Publications (1)

Publication Number Publication Date
ATE301131T1 true ATE301131T1 (de) 2005-08-15

Family

ID=22325486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972640T ATE301131T1 (de) 1998-11-19 1999-11-19 Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung

Country Status (8)

Country Link
US (2) US7491796B1 (de)
EP (1) EP1131344B1 (de)
JP (1) JP4566406B2 (de)
AT (1) ATE301131T1 (de)
AU (1) AU1174400A (de)
CA (1) CA2349290A1 (de)
DE (1) DE69926531T2 (de)
WO (1) WO2000031123A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131344B1 (de) * 1998-11-19 2005-08-03 ELAN CORPORATION, Plc Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung
AUPR272901A0 (en) * 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
DK2734634T3 (da) * 2011-07-22 2019-10-21 Univ Chicago Igf-1 til anvendelse til behandling af migræne
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
EP4027984A4 (de) 2019-09-09 2023-10-18 The University of Chicago Kombinationstherapie zur behandlung von migräne

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1091138A (zh) * 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
EP1281718A3 (de) * 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptiden die den Transport über Geweben erhöhen
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US6703362B1 (en) * 1997-05-15 2004-03-09 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
AU755154B2 (en) * 1997-05-15 2002-12-05 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
EP1131344B1 (de) * 1998-11-19 2005-08-03 ELAN CORPORATION, Plc Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung

Also Published As

Publication number Publication date
CA2349290A1 (en) 2000-06-02
JP2002530429A (ja) 2002-09-17
US7491796B1 (en) 2009-02-17
EP1131344B1 (de) 2005-08-03
US20090238886A1 (en) 2009-09-24
EP1131344A2 (de) 2001-09-12
AU1174400A (en) 2000-06-13
DE69926531T2 (de) 2006-03-30
JP4566406B2 (ja) 2010-10-20
WO2000031123A3 (en) 2000-11-09
WO2000031123A2 (en) 2000-06-02
DE69926531D1 (de) 2005-09-08

Similar Documents

Publication Publication Date Title
EP2301531A3 (de) Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
DE69835692D1 (de) Geladene lipide und deren verwendung
WO1998051325A3 (en) Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
DK0949907T3 (da) Fremgangsmåder og præparater til forbedret biotilgængelighed og biologisk aktive midler til slimhindeadministration
ATE455561T1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
ATE414491T1 (de) Implantierbare arzneiabgabevorrichtung mit drahtfäden
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
EP2266590A3 (de) Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
ATE401874T1 (de) Verabreichung von capsaicinoiden
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
CY1109661T1 (el) 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
WO2007046103A3 (en) System for iontophoretic transdermal delivery of polymeric agents and methods of use thereof
BR9811094A (pt) Agente terapêutico para tumores linfáticos
WO2006083961A3 (en) Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
DK0981362T3 (da) Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
DE69926531D1 (de) Gegen gastrointestinale transport rezeptoren gerichtete retro-invertierte peptide und deren verwendung
ATE364315T1 (de) Tgf-alpha polypeptide, funktionelle fragmente und verfahren zu ihrer anwendung
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
PT1233786E (pt) Produto contendo pelo menos uma substancia inibidora das no sintases associada a pelo menos uma substancia inibidora das fosfolipases a2 para preparacao de um medicamento
WO2002010418A3 (en) Targeting through integrins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties